PCVX (Vaxcyte, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PCVX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Elvia Cowan | SVP, Finance & CAO | F | — | — |
| 2026-09-09 | ANDREW GUGGENHIME | PRESIDENT AND CFO | F | — | — |
| 2026-09-09 | Jim Wassil | EVP, Chief Scientific Ofc, COO | MIXED | — | — |
| 2026-09-09 | Luis Jodar | Chief Medical Officer | A | — | — |
| 2026-09-09 | GRANT PICKERING | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-09-09 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | F | — | — |
| 2026-09-02 | Elvia Cowan | SVP, Finance & CAO | F | — | — |
| 2026-09-02 | ANDREW GUGGENHIME | PRESIDENT AND CFO | F | — | — |
| 2026-09-02 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | F | — | — |
| 2026-09-02 | Jim Wassil | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2026-09-02 | GRANT PICKERING | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-08-05 | Jim Wassil | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2026-08-05 | ANDREW GUGGENHIME | PRESIDENT AND CFO | MIXED | — | — |
| 2026-08-05 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | MIXED | — | — |
| 2026-07-28 | GRANT PICKERING | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-07-16 | John Markels | Director | A | — | — |
| 2026-07-06 | ANDREW GUGGENHIME | PRESIDENT AND CFO | MIXED | — | — |
| 2026-07-06 | Jim Wassil | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2026-06-26 | GRANT PICKERING | CHIEF EXECUTIVE OFFICER | Sell | — | — |
| 2026-06-23 | Moncef Slaoui | Director | A | — | — |
| 2026-06-18 | GRANT PICKERING | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-06-18 | ANDREW GUGGENHIME | PRESIDENT AND CFO | MIXED | — | — |
| 2026-06-16 | Heath Lukatch | Director | A | — | — |
| 2026-06-16 | Halley E Gilbert | Director | A | — | — |
| 2026-06-16 | Jacks Lee | Director | A | — | — |
| 2026-06-16 | OLIVIER BRANDICOURT | Director | A | — | — |
| 2026-06-16 | Anne S Drapeau | Director | A | — | — |
| 2026-06-16 | Teri Loxam | Director | A | — | — |
| 2026-06-16 | John Furey | Director | A | — | — |
| 2026-06-16 | Carlos V Paya | Director | A | — | — |
| 2026-06-03 | Jim Wassil | CHIEF OPERATING OFFICER | Sell | — | — |
| 2026-05-01 | Jim Wassil | CHIEF OPERATING OFFICER | Sell | — | — |
| 2026-04-08 | Elvia Cowan | SVP, Finance & CAO | MIXED | — | — |
| 2026-04-03 | Jim Wassil | CHIEF OPERATING OFFICER | Sell | — | — |
| 2026-03-18 | Elvia Cowan | SVP, Finance & CAO | Sell | — | — |
| 2026-03-11 | ANDREW GUGGENHIME | PRESIDENT AND CFO | F | — | — |
| 2026-03-11 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | F | — | — |
| 2026-03-11 | Jim Wassil | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2026-03-11 | Elvia Cowan | SVP, Finance & CAO | MIXED | — | — |
| 2026-03-11 | GRANT PICKERING | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-03-02 | ANDREW GUGGENHIME | PRESIDENT AND CFO | MIXED | — | — |
| 2026-03-02 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | MIXED | — | — |
| 2026-03-02 | Elvia Cowan | SVP, Finance & CAO | MIXED | — | — |
| 2026-03-02 | GRANT PICKERING | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-03-02 | Jim Wassil | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2026-01-16 | ANDREW GUGGENHIME | PRESIDENT AND CFO | G | — | — |
| 2026-01-16 | GRANT PICKERING | CHIEF EXECUTIVE OFFICER | G | — | — |
| 2026-01-16 | OLIVIER BRANDICOURT | Director | A | — | — |
| 2026-01-02 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | Sell | — | — |
| 2025-12-29 | Elvia Cowan | SVP, FINANCE | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,283,818 | — |
| — | 10%+ Owner | 5,169,254 | — |
| — | 10%+ Owner | 5,074,574 | — |
| — | Director | 4,168,718 | — |
| — | Director | 2,309,554 | — |
| — | Director | 1,577,316 | — |
| — | CHIEF EXECUTIVE OFFICER | 563,117 | — |
| — | PRESIDENT AND CFO | 157,166 | — |
| — | EVP, Chief Scientific Ofc, COO | 145,435 | — |
| — | Chief Technical Ops Officer | 68,085 | — |
| — | VP, Research | 67,827 | — |
| — | Director | 66,684 | — |
| — | Chief Medical Officer | 52,632 | — |
| — | SVP, GEN COUNSEL & CORP SEC | 41,732 | — |
| — | SVP, Finance & CAO | 27,860 | — |
| — | Director | 19,481 | — |
| — | Director | 14,288 | — |
| — | SVP Process Dev, Manufacturing | 13,822 | — |
| — | Director | 12,481 | — |
| — | Director | 12,481 | — |
| — | Director | 12,481 | — |
| — | Director | 12,481 | — |
| — | Director | 6,856 | — |
| — | Director | 5,625 | — |
| — | Director | 5,306 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PCVX quote page; the site-wide leaderboard is on the insider transactions hub.